Currently, targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PD-1 has provided superior anticancer effects in colorectal and lung cancer compared to conventional chemotherapy (1). The gene discussed is CTLA4; the disease is lung cancer.